A decade of progress in the discovery and development of 'atypical' antipsychotics.
MacDonald
Gregor J
GJ
Neuroscience Medicinal Chemistry, Johnson & Johnson, Pharmaceutical Research & Development, Janssen Pharmaceutica N.V., Beerse, Belgium.
Bartolomé
José Manuel
JM
D014150:Antipsychotic Agents / Q000737:chemistry / Q000266:history / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D055808:Drug Discovery; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D015394:Molecular Structure; D017448:Receptors, Dopamine D2 / Q000819:agonists; D050637:Receptors, Dopamine D3 / Q000037:antagonists & inhibitors; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists; D018042:Receptors, Neurokinin-3 / Q000037:antagonists & inhibitors; D058830:Serotonin 5-HT2 Receptor Antagonists / Q000494:pharmacology
D014150:Antipsychotic Agents; D065127:Dopamine D2 Receptor Antagonists; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D018094:Receptors, Metabotropic Glutamate; D018042:Receptors, Neurokinin-3; D058830:Serotonin 5-HT2 Receptor Antagonists